Eris Lifesciences Ltd vs Mangalam Drugs And Organics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1340 as of 18 May 15:30 . The P/E Ratio of ERIS Lifesciences Ltd changed from 29.2 on March 2024 to 20.4 on March 2023 . This represents a CAGR of -6.92% over 5 yearsThe P/E Ratio of Mangalam Drugs and Organics Ltd changed from 17.5 on March 2025 to 0 on March 2023 . This represents a CAGR of -100.00% over 4 years The Market Cap of ERIS Lifesciences Ltd changed from ₹ 11442 crore on March 2024 to ₹ 7779 crore on March 2023 . This represents a CAGR of -7.43% over 5 yearsThe Market Cap of Mangalam Drugs and Organics Ltd changed from ₹ 146.65 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of ERIS Lifesciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 807.59 crore. This represent the decline of -100% The revenue of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ 67.38 crore as compare to the Dec '25 revenue of ₹ 58.6 crore. This represent the growth of 14.98% The ebitda of ERIS Lifesciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 264.51 crore. This represent the decline of -100% The ebitda of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ -5.53 crore as compare to the Dec '25 ebitda of ₹ -1.32 crore. This represent the growth of 318.94% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ -13.42 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of ERIS Lifesciences Ltd changed from 21.3 % on March 2021 to 129.35 % on March 2025 . This represents a CAGR of 43.44% over 5 yearsThe Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Limited was initially incorporated as 'Advent Pharma Private Limited' on April 18, 1972.
On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited.
Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001.
The company was established to set up a plant for manufacture of organic and inorganic chemicals. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.

FAQs for the comparison of ERIS Lifesciences Ltd and Mangalam Drugs and Organics Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Mangalam Drugs and Organics Ltd?

Market cap of ERIS Lifesciences Ltd is 18,572 Cr while Market cap of Mangalam Drugs and Organics Ltd is 48 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Mangalam Drugs and Organics Ltd?

The stock performance of ERIS Lifesciences Ltd and Mangalam Drugs and Organics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Mangalam Drugs and Organics Ltd?

As of May 18, 2026, the ERIS Lifesciences Ltd stock price is INR ₹1340.3. On the other hand, Mangalam Drugs and Organics Ltd stock price is INR ₹30.38.

How do dividend payouts of ERIS Lifesciences Ltd and Mangalam Drugs and Organics Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Mangalam Drugs and Organics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.